Logo

    astrazeneca

    Explore " astrazeneca" with insightful episodes like "Ashley Gaines - Vice President, Head of Breast Cancer Franchise, US Oncology Business Unit, AstraZeneca - Transforming The Diagnosis And Treatment Of Breast Cancer", "2.3 Vaccine waning", "LIVE Saturday Health Q&A!", ""WATCH THE WATER" ~ Dr. Bryan Ardis" and "All my neighbours who took the shots are dropping like flies! (So sad)" from podcasts like ""Progress, Potential, and Possibilities", "15 Minutes on Health Inequalities", "So Ready For Health's Podcast", "So Ready For Health's Podcast" and "So Ready For Health's Podcast"" and more!

    Episodes (100)

    Ashley Gaines - Vice President, Head of Breast Cancer Franchise, US Oncology Business Unit, AstraZeneca - Transforming The Diagnosis And Treatment Of Breast Cancer

    Ashley Gaines - Vice President, Head of Breast Cancer Franchise, US Oncology Business Unit, AstraZeneca - Transforming The Diagnosis And Treatment Of Breast Cancer

    Ashley Gaines is Vice President, Head of Breast Cancer Franchise, US Oncology Business Unit, at AstraZeneca ( https://www.astrazeneca-us.com/az-in-us/ashley-gaines.html ) where she is responsible for overseeing commercialization in the US for ENHERTU, TRUQAP and future breast cancer assets and indications. Ashley joined AstraZeneca in 2014 and has led commercial teams across various US and Global franchises, including Infectious Disease, Women’s Cancers, Lung Cancer and Hematologic Cancers. Her experience prior to AstraZeneca includes marketing and strategy, investment banking and management consulting roles at Pfizer, McKinsey & Co. and Goldman, Sachs & Co. Ashley has a Bachelor of Arts, Math and Urban Studies, from University of Pennsylvania, and a Master of Business Administration, General Management, from Harvard Business School. 

    Support the show

    2.3 Vaccine waning

    2.3 Vaccine waning

    Timed to coincide with 2022 European Public Health Week’s daily theme on “Vaccination as key prevention strategy”, Alastair Leyland and Anna Pearce speak to Vittal Katikireddi from the SPHSU about his work examining waning of the AstraZeneca vaccine. 

     

    Read the published Lancet paper detailing this work.

    Visit the MRC/CSO Social and Public Health Sciences Unit website.
    Follow us on Twitter.
    Follow Alastair on Twitter.
    Follow Vittal on Twitter.

    Mar 28, 2022 - Fetch.ai raised $150 million, Credit Kudos, was acquired by Apple for over $150 million.

    Mar 28, 2022 - Fetch.ai raised $150 million, Credit Kudos, was acquired by Apple for over $150 million.

    Welcome back to United Kingdom Tech Weekly Deals Roundup, a weekly podcast by Tracxn for key startup deals in the United Kingdom from last week. 

    In this edition, we will cover funding rounds of Fetch.ai, Huma, Skyports, and more. In exits, we will cover the acquisition of Credit Kudos by Apple among others.

    Starting with our deep dive into funding rounds, tech companies in the United Kingdom raised close to $331 million of funding across 29 funding rounds during this week.

    In a major funding round event, Cambridge-based Enterprise Applications startup, Fetch.ai, raised $150 million in a Series A funding round led by MEXC Global with participation from Bybit and Huobi. Fetch.ai is a blockchain-based application development platform. Fetch.ai provides an open access-based, tokenized, and decentralized machine learning network to deliver a self-organizing framework for transactions. The system consists of autonomous digital agents that can transact independently of human intervention and can represent people, machines, or themselves. Fetch.ai allows users to buy and sell digital assets autonomously with contracts, payments, and execution. Founded in 2017 by University of Cambridge alumni, Fetch.ai has raised close to $172 million till date.

    HealthTech startup, Huma, raised $33 million in a Series C funding round led by AstraZeneca. Huma is a developer of an app suite for patients and doctors. The product offerings are Medopad - a remote patient monitoring app, and Biobeats - an app and wearable device that measures health data such as heart rate variability, sleep patterns, activity, and mood that are collected in real-time for employees. Huma provides continuous blood pressure monitoring without a cuff. Founded in 2011by University of Oxford alumni, London-based Huma has raised $190 million till date.

    London-based Auto Tech startup, Skyports, raised $23 million in a Series B funding round from SolarVentus, Irelandia Aviation, Greenpoint Ventures, and others. Skyports is a provider of solutions for operating vertiports and drone delivery management. It provides software for managing airport passengers and cargo, as well as end-to-end drone delivery management solutions for medical, e-commerce, and logistics companies. Founded in 2017 by Harvard Business School alumni and University of Oxford alumni, Skyports has raised $38 million till date.

    Shufti Pro, a FinTech startup, raised $20 million in a Series A funding round led by Updata. Shufti Pro is a provider of KYC and AML solutions for businesses. Shufti Pro features machine learning-based solutions for face identification and the verification of addresses, documents, handwritten notes, customers and investors, and more. It offers integration with Android and iOS devices, APIs, and hosted KYC. Founded in 2017, London-based Shufti Pro has raised $20 million till date.

    FinTech startup, Causal, raised $20 million in a Series A funding round led by Coatue and Accel with participation from Jeremy Stoppelman, Sam Bankman Fried, Akshay Kothari, and others. Causal offers cloud-based financial planning and predictive analytics solutions for businesses. Causal includes features such as financial planning and reporting, budget tracking, financial modeling and forecasting, data visualization, simulation, ROI calculation, sensitive analysis, performance marketing, and more. Founded in 2019 by University of Oxford alumni, Causal has raised over $25 million till date.

    This was all from the funding updates, moving on to the exits. United Kingdom Tech observed 10 exits during the week of 27 Mar 2022.

    London-based FinTech startup, Credit Kudos, was acquired by Apple for over $150 million. Credit Kudos offers open banking API solutions to check credit scores for individuals and businesses. Credit Kudos offers features such as income verification, affordability and risk insights, fraud prevention, customer management, and more. Credit Kudos aggregates and interprets transaction data to be used by lenders, brokers, and financial institutions. Founded in 2015, Credit Kudos has raised close to $13 million till date from NFT Ventures, Ascension, Christian Edouard Faes, and others.

    This was all for today, we will be back next Monday with more updates. You can subscribe to our podcast on Google Podcasts, Spotify, and Apple Podcast to stay updated. If you have any feedback, please reachout to us at podcast@tracxn.com. Thank you for tuning in today, see you next week.

    Will Novavax Save Us From Omicron?

    Will Novavax Save Us From Omicron?

    The Therapeutic Goods Administration (TGA) has approved the Novavax vaccine for use in people aged 18 or over, becoming the fourth brand of COVID-19 jab that is being deployed in Australia to fight the ongoing pandemic.

    But why do we need another vaccine, how does it differ to the ones we already have, and why are some people saying it could convince anti-vaxxers to finally get inoculated?

    The Quicky speaks to an expert in immunology to answer these questions and find out everything you need you know about Novavax.

    CREDITS 

    Host: Claire Murphy

    With thanks to: 

    Professor Cassandra Berry - Professor of Immunology at Murdoch University in Western Australia

      Producer: Claire Murphy

      Executive Producer: Siobhán Moran-McFarlane

      Audio Producer: Ian Camilleri

      Subscribe to The Quicky at... https://mamamia.com.au/the-quicky/

      CONTACT US

      Got a topic you'd like us to cover? Send us an email at thequicky@mamamia.com.au

      GET IN TOUCH:

      Feedback? We’re listening! Call the pod phone on 02 8999 9386 or email us at podcast@mamamia.com.au

      Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures.

      Just by reading or listening to our content, you’re helping to fund girls in schools in some of the most disadvantaged countries in the world - through our partnership with Room to Read. We’re currently funding 300 girls in school every day and our aim is to get to 1,000. Find out more about Mamamia at mamamia.com.au 

      Become a Mamamia subscriber: https://www.mamamia.com.au/subscribe

      See omnystudio.com/listener for privacy information.

      What You Should Know Before Getting A Booster

      What You Should Know Before Getting A Booster

      The NSW, VIC and SA governments recently decided to reduce the time between our second COVID-19 jab and third booster shots to just three months, but does the shorter timeframe mean your vaccine could be less effective?

      And what about choosing between Pfizer or Moderna; how do you know which one you should get? Does it matter? Does it depend on which vaccine you had for round one and two?

      The Quicky speaks to our favourite GP to find out the answers to these and many more questions about Australia's booster program, including whether there is any truth to reports that a third injection can miraculously heal a variety of skin conditions overnight.

      CREDITS 

      Host: Claire Murphy

      With thanks to: 

      Dr Brad McKay - Science communicator, TV host, author and podcaster who works as a GP in Sydney. He is also the author of Fake Medicine: Exposing the wellness crazes, cons and quacks costing us our health

        Producer: Claire Murphy

        Executive Producer: Siobhán Moran-McFarlane

        Audio Producer: Ian Camilleri

        Subscribe to The Quicky at... https://mamamia.com.au/the-quicky/

        CONTACT US

        Got a topic you'd like us to cover? Send us an email at thequicky@mamamia.com.au

        GET IN TOUCH:

        Feedback? We’re listening! Call the pod phone on 02 8999 9386 or email us at podcast@mamamia.com.au

        Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures.

        Just by reading or listening to our content, you’re helping to fund girls in schools in some of the most disadvantaged countries in the world - through our partnership with Room to Read. We’re currently funding 300 girls in school every day and our aim is to get to 1,000. Find out more about Mamamia at mamamia.com.au 

        Become a Mamamia subscriber: https://www.mamamia.com.au/subscribe

        See omnystudio.com/listener for privacy information.

        Las noticias de la tarde del jueves 13 de enero de 2022

        Las noticias de la tarde del jueves 13 de enero de 2022

        España aprueba la dosis de refuerzo de la vacuna contra el covid para todos los mayores de 18, una cuarta dosis para pacientes de “muy alto riesgo” y fija el precio máximo de los test de antígenos en 2,94 euros; una decisión no exenta de críticas.

        Este jueves, se conmemora el Día Mundial de Lucha contra la Depresión: 280 millones de personas viven con este trastorno emocional; y el Ministerio de Igualdad hace balante de los datos de 2021 en materia de Violencia de Género.

        Edición: Ismael Arranz
        Realización: Gustavo Luna

         

        See omnystudio.com/listener for privacy information.

        Las noticias de la mañana del jueves 16 de diciembre de 2021

        Las noticias de la mañana del jueves 16 de diciembre de 2021

        La Comisión de Salud Pública, estudiará hoy la posibilidad de ampliar la dosis de refuerzo contra el Covid-19, a los mayores y a los vacunados con AstraZeneca, como ya plantearon y recomendaron ayer los expertos en la ponencia de vacunas. Adelantamos los últimos datos sobre la campaña de vacunación infantil y sobre el Plan de Acción Primaria y Comunitaria 2022-2023, que tiene, entre otras cosas, una financiación finalista.

        En clave legislativa, el Pleno del Congreso aprobará la Ley Orgánica de Formación Profesional y, en clave judicial, Caso Tándem, que hoy acoge el testimonio de uno de los principales encausados... el también comisario, Enrique García Castaño, conocido en el entorno policial como, El Gordo.

        Además, aportamos la última información sobre la emergencia volcánica que parece que llega a su fin.

        El precio de la electricidad en el mercado mayorista que cumple nuevo récord, superando la barrera de los 300 euros el megavatio hora y, terminamos con, "Mery Christmas", de Elton John y Ed Sheeran, que lleva su segunda semana como número uno.

        Edición: Carmen Soto.

        Realización: Susana León.

        See omnystudio.com/listener for privacy information.

        PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape

        PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape

        In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

        • Importance of germline and somatic testing
        • Adverse events associated with PARP inhibitors
        • Maintenance therapy in pancreatic cancer

        Presenters:

        Philip Agop Philip, MD, PhD, FRCP
        Professor
        School of Medicine
        Wayne State University
        Leader, Gastrointestinal Multidisciplinary Team
        Department of Oncology
        Karmanos Cancer Institute
        Detroit, Michigan

        Elena Gabriela Chiorean, MD
        Professor of Medicine
        Division of Medical Oncology
        Department of Medicine
        University of Washington
        Member
        Fred Hutchinson Cancer Research
        Seattle, Washington

        Content based on an online CME program supported by an educational grant from AstraZeneca.

        Link to full program:
        https://bit.ly/3jEehCc

        Link to associated downloadable PDF:
        https://bit.ly/3nSfTcR

        Dr. Ola Engkvist, Ph.D. - AstraZeneca - Head, Molecular AI, Discovery Sciences, R&D

        Dr. Ola Engkvist, Ph.D. - AstraZeneca - Head, Molecular AI, Discovery Sciences, R&D

        Dr. Ola Engkvist is Head of Molecular AI in Discovery Sciences, AstraZeneca R&D (https://www.astrazeneca.com/) . Dr. Engkvist did his PhD in computational chemistry at Lund University followed by a postdoc at Cambridge University. After working for two biotech companies Dr. Engkvist joined AstraZeneca in 2004. He currently leads the Molecular AI department, where the focus is to develop novel methods for ML/AI in drug design , productionalize the methods and apply the methods to AstraZeneca’s small molecules drug discovery portfolio. Dr. Engkvist's main research interests are deep learning based molecular de novo design, synthetic route prediction and large scale molecular property predictions, and he has published over 100 peer-reviewed scientific publications. Dr. Engkvist is also adjunct professor in machine learning and AI for drug design at Chalmers University of Technology and a trustee of Cambridge Crystallographic Data Center.

        Support the show

        У нас снова накопились вопросы к научному редактору «Медузы» Александру Ершову о ковиде. Например, почему чиновники за ревакцинацию, а ученые — не особенно?

        У нас снова накопились вопросы к научному редактору «Медузы» Александру Ершову о ковиде. Например, почему чиновники за ревакцинацию, а ученые — не особенно?

        После семи месяцев массовой вакцинации в Аргентине местный минздрав опубликовал очередной отчет о побочных эффектах вакцин от коронавируса, в том числе российского «Спутника V».

        В аргентинском отчете приводятся сведения о побочных эффектах после уколов «Спутника» (11,4 миллиона доз), англо-шведской AstraZeneca (11,1 миллиона доз) и китайской Sinopharm (9,7 миллиона доз). Исследование основано на данных, полученных до 31 июля 2021 года.

        Оно показывает, что всего за время вакцинации в стране зарегистрировано 50,5 тысячи случаев побочных эффектов, то есть на них жаловался каждый 157-й человек из 100 тысяч привитых. В 1004 случаях потребовалась госпитализация.

        Чаще всего жаловались на побочные эффекты после «Спутника», но количество серьезных последствий от российской вакцины все равно остается низким — менее 1% от общего числа жалоб, или 0,66 случая на 100 тысяч доз. К тому же, как отмечают авторы отчета, поскольку российская вакцина стала первой, которую стали массово вводить в стране, медики намного внимательнее обращали внимание на любые побочные эффекты — в том числе те, которые перестали фиксировать потом.

        Побочные эффекты, на которые жаловались после «Спутника», знакомы всем, кто прививался этим препаратом в России, — это головная боль и боль в мышцах и суставах, лихорадка, высокая температура. Очень редко встречались местные аденопатии (увеличение лимфоузлов), металлический привкус во рту и гипертермия.

        Девять случаев аргентинский минздрав не смог точно связать с получением российской вакцины — это три случая острой аутоиммунной реакции, пять случаев снижения количества тромбоцитов и один случай поражения оболочки сердца.

        До этого в Японии обнаружили примеси в партиях вакцины Moderna. Там минздрав приостановил использование 1,6 миллиона доз. Загрязненным препаратом потенциально привили 500 тысяч человек.

        В этом эпизоде «Что случилось» научный редактор «Медузы» Александр Ершов (в очередной раз) отвечает на вопросы о вакцинации.

        • Что полезного мы узнали из отчета аргентинского минздрава?
        • Что теперь можно сказать о побочных эффектах «Спутника V»? И вообще о «побочках» от прививок?
        • Чем больше будет производиться вакцин, тем чаще будут встречаться проблемы с их качеством (подобные японским)?
        • И кстати, уже пора идти ревакцинироваться?

        Как поддержать нашу редакцию — даже если вы в России и вам очень страшно

        HEALTHY BITE | The Pandemic As I Understand It To This Point

        HEALTHY BITE | The Pandemic As I Understand It To This Point

        With some parts of Australia currently over two months into lockdown, this week's Healthy Bite is dedicated to breaking down the Pandemic As I Understand it Up To This Point. I reflect on my conversation earlier this week with Prof Robert Booy, infectious disease pediatrician who works at the University of Sydney in vaccinology, take a look at the impact COVID-19 has had on the world in the past 18 months and offer ways we can improve our own immune function to promote better long term health.

        ---- 

        You can also watch this episode at https://drronehrlich.com/ 

        -----

        TIME TO TAKE CONTROL OF YOUR HEALTH? Join me in my online health programs. 

        -----

        CONNECT WITH ME

        You can ask questions via social media using my Instagram or Facebook or YouTube page.

        See omnystudio.com/listener for privacy information.

        Prof Robert Booy: Vaccinations, Herd Immunity, and the Delta Variant

        Prof Robert Booy: Vaccinations, Herd Immunity, and the Delta Variant

        My guest this week is Professor Robert Booy, an infectious diseases paediatrician who works at the University of Sydney in vaccinology, epidemiology, and infectious diseases. In our conversation, we discuss the varied perspectives on the pandemic, the delta variant, how vaccines work, AstraZeneca and clotting risks, along with what the future might look like when it comes to vaccine passports and achieving herd immunity. 

        CREDITS:

        Host: Dr Ron Ehrlich

        Guest: Professor Robert Booy

        Producer: Amelia Navascues

        For more on Prof Robert Booy’s work ...https://www.sydney.edu.au/medicine-health/about/our-people/academic-staff/robert-booy.html

        ----

         

        You can also watch this episode at www.DrRonEhrlich.com.

         

        -----

         

        TIME TO TAKE CONTROL OF YOUR HEALTH? Join me in my online health programs.

         

        -----

         

        CONNECT WITH ME

         

        You can ask questions via social media using my Instagram or Facebook or YouTube page.

        See omnystudio.com/listener for privacy information.

        A Vaccine With Free Roadside Assistance

        A Vaccine With Free Roadside Assistance

        It's a Monday and we've lost the plot. Although that's not really that unusual anymore... 

        Harley's been vaxxed and can now hear Bill Gates in his brain, plus Nikki's neighbour is complaining her car's not soundproof enough... And, honestly, I'm sure we'd all rather our car's be more soundproof so we can belt out the Backstreet Boys in PEACE. 

        No? ... Just me then. 

        LINKS

        CREDITS
        Hosts: Harley Breen & Nikki Britton 

        Senior Producer & Editor: Rachael Hart

        Managing Producer: Elle Beattie 

        Editor: Adrian Walton

        Find more great podcasts like this at novapodcasts.com.au

        See omnystudio.com/listener for privacy information.

        Morning Bell 2 July

        Morning Bell 2 July

        The Aussie share market is set to rebound, with the futures suggesting a 0.4% lift to 7,205 points. 

        US equities had a positive run, with all three major benchmarks closing higher. 

        What to watch today:

        • Zip (ASX:Z1P) announced their partnership with fintech company Propell Holdings (ASX:PHL), making the company the first BNPL service on the Propell platform. Yesterday Zip’s share price rose 1.7% and Propell’s share price jumped just over 42%. 
        • Increases in superannuation payments came into effect yesterday, bumping up from 9.5 to 10%. This sees an additional $233 in super accounts for 6.7 million Aussies. 
        • New home loan data will be released at 11:30am AEST. 
        • Keep an eye on travel stocks as Sydney, Perth, Brisbane and Darwin are in lockdown and state borders have also been closing.
        • The oil price rose 2.1% and is trading at US$75 a barrel. The gold price is up 0.4%, copper is down 1.1% and the iron ore price is trading 1.3% lower.
        • CSL Limited (ASX:CSL) was one of the most traded stocks by our advised clients yesterday. The conflicting news headlines regarding health precautions for young people taking the AstraZeneca vaccine have correlated to CSL’s fall.
        • Bell Direct clients were also trading Australia and New Zealand Bank (ASX:ANZ), Nuix (ASX:NXL), and BetMakers Technology (ASX:BET). 

        Trading ideas:

        • Bell Potter maintain their BUY recommendation on The a2 Milk Company (ASX:A2M) and maintain their $8.50 price target, with confidence in the company’s long-term potential in their distribution points in China. 
        • Bell Potter also maintain their SELL recommendation on infection prevention company Nanosonics (ASX:NAN), due to likely downgrades from its $130 million consensus revenue for FY22. 
        • Bullish charting signals have been seen for Fenix Resources (ASX:FEX), Red River Resources (ASX:RVR) and Humm Group (ASX:HUM), according to Trading Central.